Cargando…
Psilocybin in Palliative Care: An Update
PURPOSE OF REVIEW: This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106897/ https://www.ncbi.nlm.nih.gov/pubmed/37305379 http://dx.doi.org/10.1007/s13670-023-00383-7 |
_version_ | 1785026507878432768 |
---|---|
author | Whinkin, Emily Opalka, Moira Watters, Conor Jaffe, Atara Aggarwal, Sunil |
author_facet | Whinkin, Emily Opalka, Moira Watters, Conor Jaffe, Atara Aggarwal, Sunil |
author_sort | Whinkin, Emily |
collection | PubMed |
description | PURPOSE OF REVIEW: This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but is not yet approved for therapeutic use in the United States. Using targeted database and gray literature searches, and author recall, key sources were identified, reviewed, and synthesized as to the safety and efficacy of psilocybin in palliative care. RECENT FINDINGS: Life-threatening or life-limiting illnesses and faced by palliative care patients are comorbid with emotional and spiritual distress. Research and field reports reviewed suggest that psilocybin has significant and in some cases, sustained anxiolytic, antidepressant, anti-inflammatory and entheogenic effects with a favorable safety profile. Limitations of the research include the risk for selection bias toward healthy, white, financially privileged individuals, and in general, follow-up timelines too short to appropriately evaluate durability of outcomes in psychospiritual benefits and quality of life. SUMMARY: While more research is needed for palliative care populations specifically, reasonable inferences can be made regarding the potential for benefit to palliative care patients from psilocybin’s demonstrated anxiolytic, antidepressant, anti-inflammatory and entheogenic effects. However, major legal, ethical and financial barriers to access exist for the general population; obstacles which are likely worsened for geriatric and palliative care patients. Empiric treatment and large-scale controlled trials of psilocybin should be conducted to further investigate the findings of the smaller studies reviewed here across a variety of populations, for a greater understanding of therapeutic benefit and clinically relevant safety criteria, and to support thoughtful legalization and medical access. |
format | Online Article Text |
id | pubmed-10106897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101068972023-04-18 Psilocybin in Palliative Care: An Update Whinkin, Emily Opalka, Moira Watters, Conor Jaffe, Atara Aggarwal, Sunil Curr Geriatr Rep Review PURPOSE OF REVIEW: This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but is not yet approved for therapeutic use in the United States. Using targeted database and gray literature searches, and author recall, key sources were identified, reviewed, and synthesized as to the safety and efficacy of psilocybin in palliative care. RECENT FINDINGS: Life-threatening or life-limiting illnesses and faced by palliative care patients are comorbid with emotional and spiritual distress. Research and field reports reviewed suggest that psilocybin has significant and in some cases, sustained anxiolytic, antidepressant, anti-inflammatory and entheogenic effects with a favorable safety profile. Limitations of the research include the risk for selection bias toward healthy, white, financially privileged individuals, and in general, follow-up timelines too short to appropriately evaluate durability of outcomes in psychospiritual benefits and quality of life. SUMMARY: While more research is needed for palliative care populations specifically, reasonable inferences can be made regarding the potential for benefit to palliative care patients from psilocybin’s demonstrated anxiolytic, antidepressant, anti-inflammatory and entheogenic effects. However, major legal, ethical and financial barriers to access exist for the general population; obstacles which are likely worsened for geriatric and palliative care patients. Empiric treatment and large-scale controlled trials of psilocybin should be conducted to further investigate the findings of the smaller studies reviewed here across a variety of populations, for a greater understanding of therapeutic benefit and clinically relevant safety criteria, and to support thoughtful legalization and medical access. Springer US 2023-04-14 2023 /pmc/articles/PMC10106897/ /pubmed/37305379 http://dx.doi.org/10.1007/s13670-023-00383-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Whinkin, Emily Opalka, Moira Watters, Conor Jaffe, Atara Aggarwal, Sunil Psilocybin in Palliative Care: An Update |
title | Psilocybin in Palliative Care: An Update |
title_full | Psilocybin in Palliative Care: An Update |
title_fullStr | Psilocybin in Palliative Care: An Update |
title_full_unstemmed | Psilocybin in Palliative Care: An Update |
title_short | Psilocybin in Palliative Care: An Update |
title_sort | psilocybin in palliative care: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106897/ https://www.ncbi.nlm.nih.gov/pubmed/37305379 http://dx.doi.org/10.1007/s13670-023-00383-7 |
work_keys_str_mv | AT whinkinemily psilocybininpalliativecareanupdate AT opalkamoira psilocybininpalliativecareanupdate AT wattersconor psilocybininpalliativecareanupdate AT jaffeatara psilocybininpalliativecareanupdate AT aggarwalsunil psilocybininpalliativecareanupdate |